Royal Bank of Canada
CLVS

Royal Bank of Canada’s Clovis Oncology, Inc. CLVS Stock Holding History

Royal Bank of Canada’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-459,299
Closed -$547K – 8095
2022
Q3 		$547K Buy
459,299
+17,574
+4% +$27.4K ﹤0.01% 3965
2022
Q2 		$796K Sell
441,725
-39,580
-8% -$58.4K ﹤0.01% 3696
2022
Q1 		$973K Sell
481,305
-17,502
-4% -$34.4K ﹤0.01% 3669
2021
Q4 		$1.35M Buy
498,807
+109,076
+28% +$403K ﹤0.01% 3524
2021
Q3 		$1.74M Buy
389,731
+52,237
+15% +$252K ﹤0.01% 3187
2021
Q2 		$1.96M Buy
337,494
+109,849
+48% +$644K ﹤0.01% 3087
2021
Q1 		$1.6M Sell
227,645
-1,395
-0.6% -$9.35K ﹤0.01% 3195
2020
Q4 		$1.1M Sell
229,040
-31,601
-12% -$160K ﹤0.01% 3409
2020
Q3 		$1.52M Buy
260,641
+35,471
+16% +$212K ﹤0.01% 2925
2020
Q2 		$1.52M Buy
225,170
+210,807
+1,468% +$1.6M ﹤0.01% 2841
2020
Q1 		$91K Sell
14,363
-14,715
-51% -$118K ﹤0.01% 4839
2019
Q4 		$303K Sell
29,078
-13,180
-31% -$95.8K ﹤0.01% 4329
2019
Q3 		$166K Buy
42,258
+3,352
+9% +$27.1K ﹤0.01% 4559
2019
Q2 		$578K Buy
38,906
+6,988
+22% +$126K ﹤0.01% 3755
2019
Q1 		$793K Buy
31,918
+6,222
+24% +$156K ﹤0.01% 3379
2018
Q4 		$462K Buy
25,696
+15,073
+142% +$308K ﹤0.01% 3766
2018
Q3 		$312K Sell
10,623
-116,140
-92% -$4.5M ﹤0.01% 4221
2018
Q2 		$5.76M Sell
126,763
-57,765
-31% -$2.81M ﹤0.01% 1912
2018
Q1 		$9.74M Buy
184,528
+105,584
+134% +$6.16M ﹤0.01% 1559
2017
Q4 		$5.37M Sell
78,944
-3,568
-4% -$249K ﹤0.01% 2013
2017
Q3 		$6.8M Buy
82,512
+22,818
+38% +$1.81M ﹤0.01% 1786
2017
Q2 		$5.59M Buy
59,694
+58,303
+4,191% +$3.57M ﹤0.01% 1880
2017
Q1 		$88K Buy
1,391
+172
+14% +$10.5K ﹤0.01% 4832
2016
Q4 		$53K Sell
1,219
-225,714
-99% -$7.94M ﹤0.01% 5224
2016
Q3 		$8.18M Buy
226,933
+208,721
+1,146% +$4.48M ﹤0.01% 1620
2016
Q2 		$250K Buy
18,212
+17,375
+2,076% +$254K ﹤0.01% 4245
2016
Q1 		$17K Sell
837
-70
-8% -$1.48K ﹤0.01% 5560
2015
Q4 		$33K Sell
907
-12,700
-93% -$819K ﹤0.01% 5513
2015
Q3 		$1.25M Buy
13,607
+5,557
+69% +$481K ﹤0.01% 2669
2015
Q2 		$708K Sell
8,050
-7,850
-49% -$672K ﹤0.01% 3238
2015
Q1 		$1.18M Buy
15,900
+7,363
+86% +$520K ﹤0.01% 2714
2014
Q4 		$478K Sell
8,537
-7,863
-48% -$413K ﹤0.01% 3607
2014
Q3 		$744K Buy
16,400
+8,500
+108% +$355K ﹤0.01% 3091
2014
Q2 		$327K Sell
7,900
-3,500
-31% -$180K ﹤0.01% 3805
2014
Q1 		$790K Buy
11,400
+950
+9% +$69.8K ﹤0.01% 2973
2013
Q4 		$630K Buy
10,450
+9,876
+1,721% +$537K ﹤0.01% 3233
2013
Q3 		$35K Buy
+574
New +$40.7K ﹤0.01% 4962

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Royal Bank of Canada's CLVS Position: Q4 2022 in Review

Royal Bank of Canada sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 459,299 shares — an estimated $547K sold.

Royal Bank of Canada first reported a position in CLVS in Q3 2013 and held it in 37 quarters. The position peaked at $9.74M in Q1 2018. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Royal Bank of Canada reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 459,299 Clovis Oncology, Inc. shares in Q4 2022, an estimated $547K.
  • Royal Bank of Canada first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 37 quarters.
  • Royal Bank of Canada's Clovis Oncology, Inc. position peaked at $9.74M in Q1 2018.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Royal Bank of Canada's 13F filing for Q4 2022, filed 14 Feb 2023.